{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:17:46Z","timestamp":1789208266447,"version":"build-2803163510"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Corporation of Long Island"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Opioid use disorder (OUD) confers increased risk of contracting bloodborne and sexually transmitted infections (STIs). Limited data exist on infectious disease screening and preexposure prophylaxis (PrEP) usage among United States Veterans (USVs) with OUD, including persons who inject drugs (PWID). This study aimed to evaluate the epidemiology of human immunodeficiency virus (HIV), hepatitis C virus (HCV), bacterial STIs, and PrEP uptake in USVs with OUD, including PWID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective chart review of USVs with OUD seeking care at Northport Veterans Affairs Medical Center between 2012 and 2022 was completed. Sociodemographics, HIV, HCV, STI testing rates and diagnosis, and PrEP uptake were compared between USVs, stratified by injection drug use history.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 502 USVs with OUD; 43% had a history of injection drug use. Overall, 2.2% of USVs had HIV and 28.7% had HCV. An STI was diagnosed in 10% of USVs, most frequently syphilis (1.8%). PWID were more likely to be tested for HIV (93.5% PWID vs. 73.1% non-PWID; P &amp;lt; .001), HCV (95.8% PWID vs. 80.8% non-PWID; P &amp;lt; .001), and syphilis (80% PWID vs. 69.2% non-PWID; P = .006). Total gonorrhea and chlamydia testing rates were 31.9% and 33.7%, respectively, without difference between the groups. PrEP was prescribed in 1.2% of USVs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In USVs with OUD, gonorrhea and chlamydia screening occurred less frequently than syphilis, HCV, and HIV. PWID were more likely to be screened for HIV, HCV, and syphilis. PrEP uptake was low. Both PWID and non-PWID may benefit from increased STI screening and linkage to PrEP.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofae429","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:46:13Z","timestamp":1721342773000},"source":"Crossref","is-referenced-by-count":4,"title":["Sexually Transmitted Infection (STI) Incidence, STI Screening, and Human Immunodeficiency Virus Preexposure Prophylaxis Uptake in United States Veterans With Opioid Use Disorder in Long Island, New York"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5685-2487","authenticated-orcid":false,"given":"Pronoma","family":"Srivastava","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Renaissance School of Medicine at Stony Brook University , Stony Brook, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northport Veterans Affairs Medical Center , Northport, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-4140","authenticated-orcid":false,"given":"Audun J","family":"Lier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northport Veterans Affairs Medical Center , Northport, New York , USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Northport Veterans Affairs Medical Center , Northport, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"2024082915051679400_ofae429-B1","article-title":"Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health. PEP22-07-01-005, NSDUH Series H-57","author":"Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration","year":"2023"},{"key":"2024082915051679400_ofae429-B2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S116720","article-title":"Substance use disorders in military veterans: prevalence and treatment challenges","volume":"8","author":"Teeters","year":"2017","journal-title":"Subst Abuse Rehabil"},{"key":"2024082915051679400_ofae429-B3","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1080\/07853890.2022.2092896","article-title":"U.S. military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts","volume":"54","author":"Bennett","year":"2022","journal-title":"Ann Med"},{"key":"2024082915051679400_ofae429-B4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2024082915051679400_ofae429-B5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.amepre.2019.01.016","article-title":"Changing trends in opioid overdose deaths and prescription opioid receipt among veterans","volume":"57","author":"Lin","year":"2019","journal-title":"Am J Prev Med"},{"key":"2024082915051679400_ofae429-B6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00007435-199607000-00006","article-title":"History of sexually transmitted diseases infection, drug-sex behaviors, and the use of condoms among midwestern users of injection drugs and crack cocaine","volume":"23","author":"Siegal","year":"1996","journal-title":"Sex Transm Dis"},{"key":"2024082915051679400_ofae429-B7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10900-016-0234-2","article-title":"Exchange of sex for drugs or money in adolescents and young adults: an examination of sociodemographic factors, HIV-related risk, and community context","volume":"42","author":"Boyer","year":"2017","journal-title":"J Community Health"},{"key":"2024082915051679400_ofae429-B8","doi-asserted-by":"crossref","first-page":"105779","DOI":"10.1016\/j.ypmed.2019.105779","article-title":"Sexual risk behaviors and STDs among persons who inject drugs: a national study","volume":"126","author":"Brookmeyer","year":"2019","journal-title":"Prev Med"},{"key":"2024082915051679400_ofae429-B9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1086\/318131","article-title":"Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers","volume":"31","author":"Hwang","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2024082915051679400_ofae429-B10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s10461-012-0276-0","article-title":"Non-injection and injection drug use and STI\/HIV risk in the United States: the degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users","volume":"17","author":"Khan","year":"2013","journal-title":"AIDS Behav"},{"key":"2024082915051679400_ofae429-B11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","article-title":"The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions","volume":"15","author":"Perlman","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024082915051679400_ofae429-B12","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.2019.6390","article-title":"Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement","volume":"321","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"2024082915051679400_ofae429-B13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"2024082915051679400_ofae429-B14","doi-asserted-by":"crossref","first-page":"e1917134","DOI":"10.1001\/jamanetworkopen.2019.17134","article-title":"Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis","volume":"2","author":"Ong","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2024082915051679400_ofae429-B15","article-title":"Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: clinical providers\u2019 supplement","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"2024082915051679400_ofae429-B16","article-title":"National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention. AtlasPlus","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"2024082915051679400_ofae429-B17","article-title":"U.S. Department of Veterans Affairs","author":"Veterans Health Administration"},{"key":"2024082915051679400_ofae429-B18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/ADM.0000000000001134","article-title":"Testing and case rates of gonorrhea, chlamydia, syphilis, and HIV among people with substance use disorders in the Veterans Health Administration","volume":"17","author":"Villamagna","year":"2023","journal-title":"J Addict Med"},{"key":"2024082915051679400_ofae429-B19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11606-019-05307-w","article-title":"Mortality among veterans with major mental illnesses seen in primary care: results of a national study of veteran deaths","volume":"35","author":"Trivedi","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2024082915051679400_ofae429-B20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.24875\/AIDSRev.M17000006","article-title":"HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community's infections","volume":"19","author":"Spaulding","year":"2017","journal-title":"AIDS Rev"},{"key":"2024082915051679400_ofae429-B21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.amepre.2020.06.019","article-title":"Sexual violence, mental health, and prescription opioid use and misuse","volume":"59","author":"Austin","year":"2020","journal-title":"Am J Prev Med"},{"key":"2024082915051679400_ofae429-B22","doi-asserted-by":"crossref","first-page":"108714","DOI":"10.1016\/j.drugalcdep.2021.108714","article-title":"The association of opioid use disorder and homelessness nationally in the Veterans Health Administration","volume":"223","author":"Manhapra","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2024082915051679400_ofae429-B23","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1097\/PTS.0000000000000884","article-title":"Review of reported adverse events occurring among the homeless veteran population in the Veterans Health Administration","volume":"17","author":"Soncrant","year":"2021","journal-title":"J Patient Saf"},{"key":"2024082915051679400_ofae429-B24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/add.15116","article-title":"Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration","volume":"116","author":"Lin","year":"2021","journal-title":"Addiction"},{"key":"2024082915051679400_ofae429-B25","doi-asserted-by":"crossref","first-page":"ofaa414","DOI":"10.1093\/ofid\/ofaa414","article-title":"Use of ICD-10 codes for identification of injection drug use-associated infective endocarditis is nonspecific and obscures critical findings on impact of medications for opioid use disorder","volume":"7","author":"Marks","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024082915051679400_ofae429-B26","doi-asserted-by":"crossref","first-page":"107906","DOI":"10.1016\/j.drugalcdep.2020.107906","article-title":"Validity of ICD-based algorithms to estimate the prevalence of injection drug use among infective endocarditis hospitalizations in the absence of a reference standard","volume":"209","author":"McGrew","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2024082915051679400_ofae429-B27","doi-asserted-by":"crossref","first-page":"e1649","DOI":"10.1093\/cid\/ciaa1278","article-title":"Evaluating differences in opioid and stimulant use\u2013associated infectious disease hospitalizations in Florida, 2016\u20132017","volume":"73","author":"Serota","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024082915051679400_ofae429-B28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/09540121.2020.1826396","article-title":"HIV-positive persons who inject drugs experience poor health outcomes and unmet needs for care services","volume":"33","author":"Dasgupta","year":"2021","journal-title":"AIDS Care"},{"key":"2024082915051679400_ofae429-B29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.15288\/jsad.2016.77.160","article-title":"The relationship between client characteristics and wraparound services in substance use disorder treatment centers","volume":"77","author":"Paino","year":"2016","journal-title":"J Stud Alcohol Drugs"},{"key":"2024082915051679400_ofae429-B30","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1007\/s10461-020-03151-2","article-title":"HIV infection and depression among opiate users in a US epicenter of the opioid epidemic","volume":"25","author":"Denis","year":"2021","journal-title":"AIDS Behav"},{"key":"2024082915051679400_ofae429-B31","article-title":"Ending the HIV epidemic: a plan for America","author":"Azar"},{"key":"2024082915051679400_ofae429-B32","first-page":"24","article-title":"Screening and treating hepatitis C in the VA: achieving excellence using lean and system redesign","volume":"35","author":"Park","year":"2018","journal-title":"Fed Pract"},{"key":"2024082915051679400_ofae429-B33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/10826084.2020.1858106","article-title":"Hepatitis C virus screening among Medicaid-insured individuals with opioid use disorder across substance use disorder treatment settings","volume":"56","author":"Choi","year":"2021","journal-title":"Subst Use Misuse"},{"key":"2024082915051679400_ofae429-B34","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/cid\/ciac981","article-title":"Prevalence of testing for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among Medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016\u20132019","volume":"76","author":"Ahrens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024082915051679400_ofae429-B35","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994\u20132004","volume":"46","author":"Amon","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024082915051679400_ofae429-B36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024082915051679400_ofae429-B37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(17)30676-X","article-title":"Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study","volume":"18","author":"Zelenev","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024082915051679400_ofae429-B38","author":"Centers for Disease Control and Prevention"},{"issue":"(Suppl 6)","key":"2024082915051679400_ofae429-B39","doi-asserted-by":"crossref","first-page":"e25355","DOI":"10.1002\/jia2.25355","article-title":"Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy","volume":"22","author":"Cohen","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2024082915051679400_ofae429-B40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/157016212800618138","article-title":"Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects","volume":"10","author":"Jarvis","year":"2012","journal-title":"Curr HIV Res"},{"key":"2024082915051679400_ofae429-B41","article-title":"Sexually transmitted infections national strategic plan for the United States: 2021\u20132025","author":"US Department of Health and Human Services","year":"2020"},{"issue":"RR-5","key":"2024082915051679400_ofae429-B42","first-page":"1","article-title":"Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"2024082915051679400_ofae429-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"2024082915051679400_ofae429-B44","volume-title":"Sexually transmitted infections: adopting a sexual health paradigm","author":"National Academies of Sciences, Engineering, and Medicine","year":"2021"},{"key":"2024082915051679400_ofae429-B45","doi-asserted-by":"crossref","first-page":"e2221346","DOI":"10.1001\/jamanetworkopen.2022.21346","article-title":"Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use","volume":"5","author":"Streed","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024082915051679400_ofae429-B46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","article-title":"Stigma, discrimination and the health of illicit drug users","volume":"88","author":"Ahern","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"2024082915051679400_ofae429-B47","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s11606-019-05475-9","article-title":"Roadblocks to PrEP: what medical records reveal about access to HIV pre-exposure prophylaxis","volume":"35","author":"Skolnik","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2024082915051679400_ofae429-B48","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s11606-021-07034-7","article-title":"Discussion and initiation of HIV pre-exposure prophylaxis were rare following diagnoses of sexually transmitted infections among veterans","volume":"37","author":"Kobayashi","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2024082915051679400_ofae429-B49","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/10410236.2020.1787927","article-title":"Provider-patient communication on pre-exposure prophylaxis (Prep) for HIV prevention: an exploration of healthcare provider challenges","volume":"36","author":"Wilson","year":"2021","journal-title":"Health Commun"},{"issue":"RR-14","key":"2024082915051679400_ofae429-B50","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2024082915051679400_ofae429-B51","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2024082915051679400_ofae429-B52","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/OLQ.0000000000001341","article-title":"Collateral damage: a narrative review on epidemics of substance use disorders and their relationships to sexually transmitted infections in the United States","volume":"48","author":"Strathdee","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"4 Suppl 3","key":"2024082915051679400_ofae429-B53","first-page":"iii7","article-title":"The role of sexual transmission of HIV infection among injection and non-injection drug users","volume":"80","author":"Strathdee","year":"2003","journal-title":"J Urban Health"},{"key":"2024082915051679400_ofae429-B54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11904-008-0030-4","article-title":"Variations in sexual risks in drug users: emerging themes in a behavioral context","volume":"5","author":"Celentano","year":"2008","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024082915051679400_ofae429-B55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/322020","article-title":"Sexual transmission risk among noninjecting heroin users infected with human immunodeficiency virus or hepatitis C virus","volume":"184","author":"Neaigus","year":"2001","journal-title":"J Infect Dis"},{"key":"2024082915051679400_ofae429-B56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1081\/JA-120028488","article-title":"Sharing of noninjection drug-use implements as a risk factor for hepatitis C","volume":"39","author":"Tortu","year":"2004","journal-title":"Subst Use Misuse"},{"key":"2024082915051679400_ofae429-B57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00042560-200208010-00011","article-title":"Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users","volume":"30","author":"Gyarmathy","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024082915051679400_ofae429-B58","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.15585\/mmwr.mm6743a3","article-title":"Hepatitis A virus outbreaks associated with drug use and homelessness\u2014California, Kentucky, Michigan, and Utah, 2017","volume":"67","author":"Foster","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024082915051679400_ofae429-B59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","article-title":"Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps","volume":"39","author":"Wyse","year":"2018","journal-title":"Subst Abus"},{"key":"2024082915051679400_ofae429-B60","doi-asserted-by":"crossref","first-page":"e38335","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"key":"2024082915051679400_ofae429-B61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024082915051679400_ofae429-B62","doi-asserted-by":"crossref","first-page":"ofab289","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024082915051679400_ofae429-B63","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","article-title":"Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis","volume":"73","author":"Grebely","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024082915051679400_ofae429-B64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2024082915051679400_ofae429-B65","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ajad.13413","article-title":"Trends in substance use disorder diagnoses among veterans, 2009\u20132019","volume":"32","author":"Hoggatt","year":"2023","journal-title":"Am J Addict"},{"key":"2024082915051679400_ofae429-B66","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/add.14878","article-title":"The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States","volume":"115","author":"Hoots","year":"2020","journal-title":"Addiction"},{"key":"2024082915051679400_ofae429-B67","doi-asserted-by":"crossref","first-page":"108135","DOI":"10.1016\/j.drugalcdep.2020.108135","article-title":"Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: a modeling analysis","volume":"213","author":"Cepeda","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2024082915051679400_ofae429-B68","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s10461-023-04012-4","article-title":"Does the association between stimulant use and high risk sexual behavior vary by injection drug use, sexual minority status, or HIV infection status? A meta-analysis","volume":"27","author":"Feelemyer","year":"2023","journal-title":"AIDS Behav"},{"key":"2024082915051679400_ofae429-B69","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/09540121.2019.1595523","article-title":"Effective use of pre-exposure prophylaxis (PrEP) among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles","volume":"31","author":"Goodman-Meza","year":"2019","journal-title":"AIDS Care"},{"key":"2024082915051679400_ofae429-B70","first-page":"216","volume-title":"Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020"},{"key":"2024082915051679400_ofae429-B71","article-title":"Expanding harm reduction services and implementation of syringe services programs (SSP) within Veterans Health Administration (VHA)","author":"US Department of Veterans Affairs","year":"2017"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae429\/58610180\/ofae429.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae429\/58874894\/ofae429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae429\/58874894\/ofae429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T12:10:58Z","timestamp":1732450258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae429\/7718007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae429","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,22]]},"article-number":"ofae429"}}